For instance, Docetaxel, a frequently utilized chemotherapeutic agent in the clinical setting for the treatment of GC, exhibited heightened sensitivity in the group characterized by a high UBE2C+ tumour cell score. This evidence concerns the gene UBE2C and neoplasm.